Investors with losses are encouraged to contact the firm before


August 9, 2021


; click




here




to submit trade information

LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) —


The Portnoy Law Firm


advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney


Lesley F. Portnoy



,

to determine eligibility to participate in this action, by phone 310-692-8883 or


email


, or


click here


to join the case.

It is alleged in this complaint that throughout the Class Period, AcelRx made materially misleading and false statements and/or failed to disclose that: (1) AcelRx’s disclosure controls and procedures with respect to its marketing of DSUVIA were deficient; (2) AcelRx had been making misleading or false claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays, as a result; (3) the foregoing conduct subjected AcelRx to increased regulatory enforcement and scrutiny; and (4) AcelRx’s public statements were materially false and misleading at all relevant times, as a result.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 9, 2021.

Please visit our


website


to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.

Admitted CA and NY Bar



[email protected]



310-692-8883

www.portnoylaw.com

Attorney Advertising